当前位置:药药网 / 数据中心 / 儿科研究特征电子表格
Semglee injection
通用名称
insulin glargine-yfgn
儿科标签批准日期
2021/7/28 0:00:00
特定指示/秒
Improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus
标签更改摘要
- Safety and effectiveness of insulin glargine products have been established in pediatric patients (age 6 to 15 years) with type 1 diabetes.
- Safety and effectiveness of insulin glargine products in pediatric patients younger than 6 years of age with type 1 diabetes and pediatric patients with type 2 diabetes have not been established.
- In the pediatric clinical trial, pediatric patients (age 6 to 15 years) with type 1 diabetes had a higher incidence of severe symptomatic hypoglycemia compared to the adults in trials with type 1 diabetes.
- Information on dosing, adverse reactions, and clinical trial.
- New active ingredient.
治疗类别
Hyperglycemic Agents